ConductScience.org, home

Paper17517626

Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.

Valmori D and 19 others. Proc Natl Acad Sci U S A, 2007. Cited by 251 papers, by iCite.

Cite this record

ConductScience Library. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Papers, record 17517626. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17517626

Download JSON
Disease
cancer699 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.
PubMed
Journal
Proc Natl Acad Sci U S A
PubMed
Year
2007
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
251
iCite
Relative citation ratio, by iCite
4.82
iCite
Revised in PubMed
2024-04-13
PubMed

Authors20

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Valmori DDanila
2Souleimanian NENaira E
3Tosello VValeria
4Bhardwaj NNina
5Adams SSylvia
6O'Neill DDavid
7Pavlick AAnna
8Escalon JBJuliet B
9Cruz CMCrystal M
10Angiulli AAngelica
11Angiulli FFrancesca
12Mears GGregory
13Vogel SMSusan M
14Pan LLinda
15Jungbluth AAAchim A
16Hoffmann EWEric W
17Venhaus RRalph
18Ritter GGerd
19Old LJLloyd J
20Ayyoub MMaha

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AntibodiesMajor topic
Antigens, NeoplasmMajor topic
CD8-Positive T-LymphocytesMajor topic
Cross-PrimingMajor topic
MannitolMajor topic
Membrane ProteinsMajor topic
Oleic AcidsMajor topic
OligodeoxyribonucleotidesMajor topic
Th1 CellsMajor topic
Cancer Vaccines
Epitopes, B-Lymphocyte
Humans
Immunotherapy
Neoplasms
Recombinant Proteins
Vaccination

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
K23 CA125205NCI NIH HHSUnited StatesK23CA125205PubMed and NIH

Source NIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT00299728NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several TumorsResults

Source ClinicalTrials.gov

Download CSV of trials

References39

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
110742135Monoclonal antibody therapies-a 'constant' threat to cancer.Nat Med2000https://conductscience.org/library/papers/10742135PubMed
216034368Cancer/testis antigens, gametogenesis and cancer.Nat Rev Cancer2005https://conductscience.org/library/papers/16034368PubMed
316984998Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.Proc Natl Acad Sci U S A2006https://conductscience.org/library/papers/16984998PubMed
415696196Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.J Clin Invest2005https://conductscience.org/library/papers/15696196PubMed
516541472Toll-like receptor stimulation as a third signal required for activation of human naive B cells.Eur J Immunol2006https://conductscience.org/library/papers/16541472PubMed
69547346A survey of the humoral immune response of cancer patients to a panel of human tumor antigens.J Exp Med1998https://conductscience.org/library/papers/9547346PubMed
715994128Identification of B cell epitopes recognized by antibodies specific for the tumor antigen NY-ESO-1 in cancer patients with spontaneous immune responses.Clin Immunol2005https://conductscience.org/library/papers/15994128PubMed
816507175B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome.Arthritis Res Ther2006https://conductscience.org/library/papers/16507175PubMed
911782380NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.Cancer Res2002https://conductscience.org/library/papers/11782380PubMed
1024443506Pillars article: two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999. 401: 708-712.J Immunol2014https://conductscience.org/library/papers/24443506PubMed
1112445278Cancer/testis antigens: an expanding family of targets for cancer immunotherapy.Immunol Rev2002https://conductscience.org/library/papers/12445278PubMed
1216604075Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells.Nat Immunol2006https://conductscience.org/library/papers/16604075PubMed
139892619Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization.J Exp Med1999https://conductscience.org/library/papers/9892619PubMed
1415252201Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.Proc Natl Acad Sci U S A2004https://conductscience.org/library/papers/15252201PubMed
1515546948Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery.Blood2005https://conductscience.org/library/papers/15546948PubMed
1611861616CpG motifs in bacterial DNA and their immune effects.Annu Rev Immunol2002https://conductscience.org/library/papers/11861616PubMed
177872156Molecular basis of Fc receptor function.Adv Immunol1994https://conductscience.org/library/papers/7872156PubMed
189933083Cellular requirements for the monoclonal antibody-mediated eradication of an established solid tumor.Eur J Immunol1999https://conductscience.org/library/papers/9933083PubMed
197595233Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein.J Exp Med1995https://conductscience.org/library/papers/7595233PubMed
2011429607Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction.Nature2001https://conductscience.org/library/papers/11429607PubMed

See all 39 referencesDownload CSV of references

Cited by144

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 251 citations.

PMIDTitleJournalYearIn PapersSource
42698927Mechanistic biomarkers for cancer vaccine development: from cancer cell biology to neoantigen-guided precision immunotherapy.Front Cell Dev Biol2026https://conductscience.org/library/papers/42698927PubMed
42531334DNA oligonucleotides block viral entry of SARS-CoV-2 Omicron variants.PLoS Pathog2026https://conductscience.org/library/papers/42531334PubMed
42406997TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell-CD2 Costimulatory Axis.Cancer Res2026https://conductscience.org/library/papers/42406997PubMed
40379970Recent advances in therapeutic cancer vaccines.Nat Rev Cancer2025https://conductscience.org/library/papers/40379970PubMed
40132910mTOR inhibition modulates vaccine-induced immune responses to generate memory T cells in patients with solid tumors.J Immunother Cancer2025https://conductscience.org/library/papers/40132910PubMed
39275923NY-ESO-1 antigen: A promising frontier in cancer immunotherapy.Clin Transl Med2024https://conductscience.org/library/papers/39275923PubMed
38797949An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer.Cancer Control2024https://conductscience.org/library/papers/38797949PubMed
37936697Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy.Front Immunol2023https://conductscience.org/library/papers/37936697PubMed
37731507Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment.Front Immunol2023https://conductscience.org/library/papers/37731507PubMed
37584947Th1-polarized MtrE-based gonococcal vaccines display prophylactic and therapeutic efficacy.Emerg Microbes Infect2023https://conductscience.org/library/papers/37584947PubMed
36560420Recent Advances in Cancer Vaccines: Challenges, Achievements, and Futuristic Prospects.Vaccines (Basel)2022https://conductscience.org/library/papers/36560420PubMed
35806328Dendritic Cell-Based Immunotherapy in Hot and Cold Tumors.Int J Mol Sci2022https://conductscience.org/library/papers/35806328PubMed
35737089Potent anti-tumor immune response and tumor growth inhibition induced by HER2 subdomain fusion protein in a mouse tumor model.J Cancer Res Clin Oncol2023https://conductscience.org/library/papers/35737089PubMed
35651800Fueling Cancer Vaccines to Improve T Cell-Mediated Antitumor Immunity.Front Oncol2022https://conductscience.org/library/papers/35651800PubMed
35303904Cancer vaccines as promising immuno-therapeutics: platforms and current progress.J Hematol Oncol2022https://conductscience.org/library/papers/35303904PubMed
35217574Peptidic microarchitecture-trapped tumor vaccine combined with immune checkpoint inhibitor or PI3Kγ inhibitor can enhance immunogenicity and eradicate tumors.J Immunother Cancer2022https://conductscience.org/library/papers/35217574PubMed
35017148B cells imprint adoptively transferred CD8+ T cells with enhanced tumor immunity.J Immunother Cancer2022https://conductscience.org/library/papers/35017148PubMed
34971473Cancer immunotherapy using artificial adjuvant vector cells to deliver NY-ESO-1 antigen to dendritic cells in situ.Cancer Sci2022https://conductscience.org/library/papers/34971473PubMed
34386424The Clinical Application of Neoantigens in Esophageal Cancer.Front Oncol2021https://conductscience.org/library/papers/34386424PubMed
34385817CpG-Based Nanovaccines for Cancer Immunotherapy.Int J Nanomedicine2021https://conductscience.org/library/papers/34385817PubMed

See all 144 cited byDownload CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920NCBI Gene
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
CTAG1A246100PubTator's text mininghttps://conductscience.org/library/genes/246100NCBI Gene

Download CSV of genes

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
AGATOLIMOD SODIUMCHEMBL2103793Results1https://conductscience.org/library/drugs/CHEMBL2103793ChEMBL
INCOMPLETE FREUND'S ADJUVANTCHEMBL4650400Results1https://conductscience.org/library/drugs/CHEMBL4650400ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17517626

GET https://conductscience.org/api/papers/v1/17517626/references?page=2